In some New York neighborhoods, the housing stock is great, but turnover is so low, word of mouth is the best search engine.
NYS Entity Status
NYS Filing Date
NOVEMBER 26, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2013 - PADDLE FOR THE CURE INC.
Around the Web
- Neighborhoods That Play Hard to Get
By STEFANOS CHEN - Friday Aug 11, 2017
- Power, Corruption and Murder Roil Little Guyana
By LIZ ROBBINS - Friday Oct 20, 2017
A gruesome crime in Guyana has threatened a tightly knit immigrant community in Queens, pitting Hindu against Muslim, rich against poor, and cousin against cousin.
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Why Companies Like Toys ‘R’ Us Love to Go Bust in Richmond, Va.
By MICHAEL CORKERY and JESSICA SILVER-GREENBERG - Tuesday Nov 14, 2017
The federal bankruptcy court in Virginia’s capital moves quickly, has expert judges and legal precedents that are favorable to companies, and a reputation for approving huge fees for lawyers.
- Woman Who Sabotaged Fiancé’s Kayak Is Sentenced to Up to 4 Years
By SARAH MASLIN NIR - Wednesday Nov 8, 2017
Angelika Graswald, who prosecutors said had watched her fiancé drown and even moved a paddle out of his reach, was expected to be freed by year’s end.
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.